According to Liu et al., a higher FOXP3+/CD8+ TIL ratio in tumour sites from stage III and IV NSCLC patients was associated with poor response to platinum-based chemotherapy [52]. This evidence concerns the gene FOXP3 and non-small cell lung carcinoma.